{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:00:07Z","timestamp":1761505207671,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.3816\/clc.2004.n.020","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:08:44Z","timestamp":1221080924000},"page":"43-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Docetaxel for Malignant Mesothelioma: Phase II Study of the Eastern Cooperative Oncology Group"],"prefix":"10.3816","volume":"6","author":[{"given":"Chandra P.","family":"Belani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeshna","family":"Adak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seena","family":"Aisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Levitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLC.2004.n.020_bib1","series-title":"Principles and Practice of Oncology","first-page":"1937","article-title":"Molecular Biology of Mesothelioma","author":"Testa","year":"2001"},{"key":"10.3816\/CLC.2004.n.020_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q","article-title":"New molecular and epidemiological issues in mesothelioma: Role of SV40","volume":"180","author":"Carbone","year":"1999","journal-title":"J Cell Physiol"},{"key":"10.3816\/CLC.2004.n.020_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jnci\/91.2.119","article-title":"Cell and molecular biology of Simian virus 40: Implications for human infections and disease","volume":"91","author":"Butel","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLC.2004.n.020_bib4","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLC.2004.n.020_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H","article-title":"Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma","volume":"180","author":"Murthy","year":"1999","journal-title":"J Cell Physiol"},{"key":"10.3816\/CLC.2004.n.020_bib6","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1038\/sj.onc.1201870","article-title":"Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression","volume":"16","author":"Frizelle","year":"1998","journal-title":"Oncogene"},{"key":"10.3816\/CLC.2004.n.020_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/sonc.2002.30237","article-title":"The epidemiology of mesothelioma","volume":"29","author":"Britton","year":"2002","journal-title":"Sem Oncol"},{"key":"10.3816\/CLC.2004.n.020_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.1996.14.3.1007","article-title":"Chemotherapy in malignant pleural mesothelioma. A review","volume":"14","author":"Ong","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2004.n.020_bib9","first-page":"578a","article-title":"CPT-11 in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 9733)","volume":"19","author":"Kindler","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLC.2004.n.020_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00001813-200004000-00005","article-title":"Docetaxel and irinotecan in the treatment of malignant pleural mesothelioma-a feasibility study","volume":"11","author":"Knuttila","year":"2000","journal-title":"Anti-Cancer Drugs"},{"key":"10.3816\/CLC.2004.n.020_bib11","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A phase II study of gemcitabine in patients with malignant pleural mesothelioma","volume":"85","author":"Van Meerbeeck","year":"1999","journal-title":"Cancer"},{"key":"10.3816\/CLC.2004.n.020_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/bjc.1996.465","article-title":"Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group","volume":"74","author":"Van Meerbeeck","year":"1996","journal-title":"Br J Cancer"},{"issue":"21","key":"10.3816\/CLC.2004.n.020_bib13","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"15","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2004.n.020_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00001813-200002000-00005","article-title":"In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents","volume":"11","author":"Ollikaninen","year":"2000","journal-title":"Anti-cancer Drugs"},{"key":"10.3816\/CLC.2004.n.020_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/annonc\/mdf046","article-title":"Malignant pleural mesothelioma: A phase II trial with docetaxel","volume":"13","author":"Vorobiof","year":"2002","journal-title":"Ann Oncol"},{"issue":"suppl 6","key":"10.3816\/CLC.2004.n.020_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0959-8049(01)80558-X","article-title":"Phase II study of Alimta (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma","volume":"37","author":"Scagliotti","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLC.2004.n.020_bib17","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.1999.17.10.3009","article-title":"Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin","volume":"17","author":"Th\u00f6dtmann","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2004.n.020_bib18","first-page":"495a","article-title":"Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial","volume":"19","author":"Calvert","year":"2000","journal-title":"Pro Am Soc Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411702029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411702029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:57:20Z","timestamp":1761505040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730411702029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S1525730411702029"],"URL":"https:\/\/doi.org\/10.3816\/clc.2004.n.020","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2004,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Docetaxel for Malignant Mesothelioma: Phase II Study of the Eastern Cooperative Oncology Group","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLC.2004.n.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}